BRPI0515230A - polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo - Google Patents
polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpoInfo
- Publication number
- BRPI0515230A BRPI0515230A BRPI0515230-5A BRPI0515230A BRPI0515230A BR PI0515230 A BRPI0515230 A BR PI0515230A BR PI0515230 A BRPI0515230 A BR PI0515230A BR PI0515230 A BRPI0515230 A BR PI0515230A
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- isolated
- methods
- antibodies
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Abstract
POLIPEPTìDEOS, ANTICORPOS E áCIDOS NUCLéICOS ISOLADOS, COMPOSIçõES, VETOR DE EXPRESSãO, CéLULAS HOSPEDEIRAS ISOLADAS, MéTODO PARA A PRODUçãO DE UM ANTICORPO, ARTIGOS MANUFATURADOS, MéTODOS DE TRATAMENTO E PARA O ALìVIO DE DISFUNçõES, MéTODOS DE PRODUçãO E DE SELEçãO DE UM POLIPEPTìDEO, ANTICORPO DE LIGAçãO CD2O HUMANIZADO, ANTICORPO ANTI-HER2 ISOLADO E USOS DE UM ANTICORPO A presente invenção fornece polipeptídeos que possuem regiões Fc lgG com modificações de aminoácidos que resultam em polipeptídeos que exibem funções efetoras Fc alteradas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60305704P | 2004-08-19 | 2004-08-19 | |
PCT/US2005/029511 WO2006031370A2 (en) | 2004-08-19 | 2005-08-19 | Polypeptide variants with altered effector function |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0515230A true BRPI0515230A (pt) | 2008-07-15 |
Family
ID=36060490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515230-5A BRPI0515230A (pt) | 2004-08-19 | 2005-08-19 | polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo |
Country Status (13)
Country | Link |
---|---|
US (1) | US20060067930A1 (pt) |
EP (1) | EP1778728A2 (pt) |
JP (1) | JP2008510466A (pt) |
KR (2) | KR20080080675A (pt) |
CN (1) | CN101052654A (pt) |
AU (1) | AU2005285347A1 (pt) |
BR (1) | BRPI0515230A (pt) |
CA (1) | CA2577133A1 (pt) |
IL (1) | IL181109A0 (pt) |
NO (1) | NO20071419L (pt) |
RU (1) | RU2367667C2 (pt) |
WO (1) | WO2006031370A2 (pt) |
ZA (1) | ZA200701715B (pt) |
Families Citing this family (196)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000042072A2 (en) * | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR20020027311A (ko) | 1999-05-07 | 2002-04-13 | 제넨테크, 인크. | B 세포 표면 마커에 결합하는 길항물질을 이용한자가면역 질환의 치료 |
CN101711868A (zh) | 2000-05-19 | 2010-05-26 | 杰南技术公司 | 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
MXPA03002262A (es) * | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
HUP0600342A3 (en) * | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US7984268B2 (en) * | 2002-10-08 | 2011-07-19 | Netlogic Microsystems, Inc. | Advanced processor scheduling in a multithreaded system |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
AU2004287643C1 (en) * | 2003-11-05 | 2012-05-31 | Roche Glycart Ag | CD20 antibodies with increased FC receptor binding affinity and effector function |
WO2006085967A2 (en) * | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
RS20070027A (en) | 2004-07-26 | 2008-11-28 | Biogen Idec Ma Inc., | Anti-cd154 antibodies |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
KR101027427B1 (ko) | 2004-11-12 | 2011-04-11 | 젠코어 인코포레이티드 | FcRn에 대하여 증가된 결합력을 갖는 Fc 변이체 |
US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US20060188509A1 (en) | 2005-02-23 | 2006-08-24 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
US20100104564A1 (en) * | 2005-03-29 | 2010-04-29 | Genevieve Hansen | Altered Antibody Fc Regions and Uses Thereof |
AU2006265936A1 (en) * | 2005-07-01 | 2007-01-11 | Medimmune, Llc | An integrated approach for generating multidomain protein therapeutics |
WO2007008943A2 (en) * | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
US7790655B2 (en) | 2005-10-14 | 2010-09-07 | Medimmune, Llc | Cell display of antibody libraries |
EP3056568B1 (en) | 2006-03-31 | 2021-09-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
CA2665644A1 (en) * | 2006-10-12 | 2008-05-29 | Genentech, Inc. | Antibodies to lymphotoxin-alpha |
TW200833711A (en) * | 2006-12-22 | 2008-08-16 | Genentech Inc | Antibodies to insulin-like growth factor receptor |
PE20090681A1 (es) | 2007-03-02 | 2009-06-10 | Genentech Inc | Prediccion de respuesta a un inhibidor her |
US20100183615A1 (en) * | 2007-04-03 | 2010-07-22 | Micromet Ag | Cross-species-specific bispecific binders |
HUE036885T2 (hu) | 2007-05-14 | 2018-08-28 | Astrazeneca Ab | Eljárás a bazofil-szint csökkentésére |
CA2693053C (en) | 2007-05-30 | 2021-01-05 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
DK3059246T3 (en) | 2007-09-26 | 2018-10-01 | Chugai Pharmaceutical Co Ltd | Modified constant region of an antibody |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
EP2808343B8 (en) | 2007-12-26 | 2020-01-15 | Xencor, Inc. | Fc variants with altered binding to FcRn |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
NZ602884A (en) | 2008-04-11 | 2014-08-29 | Chugai Pharmaceutical Co Ltd | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
MX2010011955A (es) | 2008-04-29 | 2011-01-21 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
US9035027B2 (en) * | 2008-06-03 | 2015-05-19 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
NZ589436A (en) * | 2008-06-03 | 2012-12-21 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
NZ590074A (en) | 2008-07-08 | 2012-12-21 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
WO2010009129A2 (en) * | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Methods of treating autoimmune diseases using cd4 antibodies |
TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
SG195558A1 (en) * | 2008-10-14 | 2013-12-30 | Genentech Inc | Immunoglobulin variants and uses thereof |
PE20120204A1 (es) * | 2008-11-17 | 2012-03-03 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas |
CA2745271A1 (en) * | 2008-12-04 | 2010-06-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
KR20110101212A (ko) | 2008-12-17 | 2011-09-15 | 제넨테크, 인크. | C형 간염 바이러스 조합 요법 |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
AU2015204268B2 (en) * | 2009-03-09 | 2017-03-02 | Bioatla, Llc | Mirac Proteins |
BRPI1008971A2 (pt) | 2009-03-09 | 2016-03-15 | Bioatla Llc | métodos para preparar uma proteína biológica condicionalmente ativa, e um modificador de resposta biológica condicionalmente ativo, proteína biológica condicionalmente ativa, e, composição farmacêutica |
BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
UA104626C2 (ru) * | 2009-06-17 | 2014-02-25 | Эббви Биотерапеутикс Инк. | Анти-vegf антитело и его применение |
TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
CA2772628A1 (en) | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
SG10201408401RA (en) | 2009-09-16 | 2015-01-29 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
AR078651A1 (es) | 2009-10-15 | 2011-11-23 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
SG182408A1 (en) * | 2010-01-11 | 2012-08-30 | Alexion Pharma Inc | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
KR20130009760A (ko) * | 2010-02-10 | 2013-01-23 | 이뮤노젠 아이엔씨 | Cd20 항체 및 이의 용도 |
AU2011225716A1 (en) * | 2010-03-11 | 2012-09-27 | Pfizer Inc. | Antibodies with pH dependent antigen binding |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
TWI667346B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
EP2575847B2 (en) | 2010-05-25 | 2022-04-27 | F. Hoffmann-La Roche AG | Methods of purifying polypeptides |
AU2011285852B2 (en) | 2010-08-03 | 2014-12-11 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
KR20130139884A (ko) | 2010-08-26 | 2013-12-23 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
JP5798307B2 (ja) * | 2010-09-03 | 2015-10-21 | 国立大学法人名古屋大学 | グロボトリアオシルセラミドを特異的に認識するモノクローナル抗体及びその作製法 |
KR20130096731A (ko) * | 2010-09-08 | 2013-08-30 | 할로자임, 아이엔씨 | 조건부 활성 치료적 단백질을 평가,확인 또는 진화시키는 방법 |
TW201631153A (zh) | 2010-11-17 | 2016-09-01 | 中外製藥股份有限公司 | 具有替代血液凝固第viii因子之功能的多重專一性抗原結合分子 |
CA2819356C (en) | 2010-11-30 | 2023-01-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
AR085403A1 (es) | 2011-02-28 | 2013-09-25 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos |
RU2607038C2 (ru) | 2011-02-28 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Антигенсвязывающие белки |
CN102675460B (zh) * | 2011-02-28 | 2015-08-19 | 珠海市丽珠单抗生物技术有限公司 | 抗肿瘤坏死因子α的人源化抗体 |
MY163539A (en) | 2011-03-29 | 2017-09-15 | Roche Glycart Ag | Antibody fc variants |
US10654916B2 (en) | 2011-04-21 | 2020-05-19 | The Regents Of The University Of California, A California Corporation | Compositions and methods for the treatment of neuromyelitis optica |
GB201114858D0 (en) * | 2011-08-29 | 2011-10-12 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of using the same |
CN110627902A (zh) | 2011-09-30 | 2019-12-31 | 中外制药株式会社 | 诱导针对靶抗原的免疫应答的抗原结合分子 |
CA3186128A1 (en) | 2011-09-30 | 2013-04-04 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting elimination of antigens |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
CN109908341B (zh) | 2011-10-14 | 2023-06-27 | 霍夫曼-拉罗奇有限公司 | Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品 |
SG11201402019TA (en) | 2011-11-02 | 2014-09-26 | Genentech Inc | Overload and elute chromatography |
KR20230143201A (ko) | 2011-11-30 | 2023-10-11 | 추가이 세이야쿠 가부시키가이샤 | 면역 복합체를 형성하는 세포내로의 운반체(캐리어)를 포함하는 의약 |
TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對il-13及/或il-17之雙特異性結合蛋白 |
CA2861124A1 (en) | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
BR112014018005B1 (pt) | 2012-02-15 | 2021-06-29 | F. Hoffmann-La Roche Ag | Uso de um complexo não covalente imobilizado |
TWI682939B (zh) | 2012-02-24 | 2020-01-21 | 日商中外製藥股份有限公司 | 經FcγRIIB促進抗原消失之抗原結合分子 |
US9751942B2 (en) | 2012-03-29 | 2017-09-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-LAMP5 antibody and utilization thereof |
EP3892638A1 (en) | 2012-05-30 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
CN104487457B (zh) | 2012-05-30 | 2018-01-26 | 中外制药株式会社 | 靶组织特异性抗原结合分子 |
CN104395339A (zh) | 2012-06-27 | 2015-03-04 | 弗·哈夫曼-拉罗切有限公司 | 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途 |
RU2015100656A (ru) | 2012-06-27 | 2016-08-20 | Ф. Хоффманн-Ля Рош Аг | Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения |
US20140004121A1 (en) | 2012-06-27 | 2014-01-02 | Amgen Inc. | Anti-mesothelin binding proteins |
CA2874554C (en) | 2012-07-13 | 2019-12-03 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
BR112015001955A2 (pt) | 2012-08-24 | 2017-11-07 | Chugai Pharmaceutical Co Ltd | variante de região fc específica de fcgamariib |
US9777067B2 (en) | 2012-09-27 | 2017-10-03 | Massachusetts Institute Of Technology | HER2- and VEGF-A-binding proteins with enhanced stability |
KR20180008921A (ko) | 2012-11-01 | 2018-01-24 | 애브비 인코포레이티드 | 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도 |
US9810670B2 (en) | 2012-11-15 | 2017-11-07 | Genentech, Inc. | Ionic strength-mediated pH gradient ion exchange chromatography |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
EP3557260B1 (en) | 2012-12-21 | 2022-05-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對gpc3標的治療劑療法為有效之患者投與的gpc3標的治療劑 |
CA2904448A1 (en) | 2013-03-15 | 2014-09-18 | Tariq Ghayur | Dual specific binding proteins directed against il-1.beta. and/or il-17 |
KR102318483B1 (ko) | 2013-04-02 | 2021-10-27 | 추가이 세이야쿠 가부시키가이샤 | Fc영역 개변체 |
RU2019115089A (ru) | 2013-04-16 | 2019-06-11 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
MX2015015060A (es) | 2013-04-29 | 2016-02-25 | Hoffmann La Roche | Anticuerpos asimetricos modificados que se unen al receptor fc y metodos de uso. |
MX364861B (es) * | 2013-04-29 | 2019-05-09 | Hoffmann La Roche | Anticuerpos anti-receptor del factor de crecimiento de tipo insulinico humano 1 (anti-igf-1r) con abolicion de la union al fcrn y su uso en el tratamiento de enfermedades oculares vasculares. |
CN105143262A (zh) | 2013-04-29 | 2015-12-09 | 豪夫迈·罗氏有限公司 | 结合人fcrn的修饰的抗体和使用方法 |
WO2014208482A1 (ja) | 2013-06-24 | 2014-12-31 | 中外製薬株式会社 | ヒト化抗Epiregulin抗体を有効成分として含む腺癌以外の非小細胞肺癌の治療剤 |
BR112016000231A8 (pt) | 2013-07-12 | 2019-12-31 | Genentech Inc | métodos para identificações de condições de separação com cromatografia de troca de íons e para análises de composições de polipeptídeos |
JP6602765B2 (ja) | 2013-09-05 | 2019-11-06 | ジェネンテック, インコーポレイテッド | クロマトグラフィー再使用のための方法 |
JP6422956B2 (ja) | 2013-10-11 | 2018-11-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性ドメイン交換共通可変軽鎖抗体 |
TW202043467A (zh) | 2013-12-04 | 2020-12-01 | 日商中外製藥股份有限公司 | 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫 |
CN105899534B (zh) | 2014-01-15 | 2020-01-07 | 豪夫迈·罗氏有限公司 | 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体 |
BR112016014969A2 (pt) | 2014-01-15 | 2018-01-23 | Hoffmann La Roche | polipeptídeo, formulação farmacêutica e uso de um polipeptídeo |
RU2725093C2 (ru) | 2014-04-25 | 2020-06-29 | Дженентек, Инк. | Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом |
JP6827319B2 (ja) | 2014-05-08 | 2021-02-10 | 中外製薬株式会社 | Gpc3標的治療剤療法が有効である患者に投与されるgpc3標的治療剤 |
EP3154586B1 (en) * | 2014-06-13 | 2020-05-27 | Mayo Foundation for Medical Education and Research | Treating lymphomas |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CN107074966A (zh) | 2014-11-06 | 2017-08-18 | 豪夫迈·罗氏有限公司 | 具有改变的FCRN‑和蛋白A‑结合性质的Fc区变体 |
MX2017005148A (es) | 2014-11-06 | 2017-08-08 | Hoffmann La Roche | Variantes de region fc con union del receptor fc neonatal (fcrn) modificado y metodos de uso. |
WO2016081746A2 (en) * | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
CN107001482B (zh) | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
CN107108726A (zh) | 2014-12-19 | 2017-08-29 | 中外制药株式会社 | 抗‑肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法 |
CN114773469A (zh) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il-8-结合抗体及其应用 |
EP3262217A4 (en) * | 2015-02-24 | 2018-07-18 | BioAtla LLC | Conditionally active biological proteins |
SG10201911335TA (en) | 2015-05-28 | 2020-01-30 | Genentech Inc | Cell-based assay for detecting anti-cd3 homodimers |
US11406715B2 (en) | 2015-05-30 | 2022-08-09 | Genentech, Inc. | Methods of treating HER2-positive metastatic breast cancer |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
WO2017046994A1 (en) | 2015-09-18 | 2017-03-23 | Chugai Seiyaku Kabushiki Kaisha | Il-8-binding antibodies and uses thereof |
EP3356415A1 (en) | 2015-09-29 | 2018-08-08 | Amgen Inc. | Asgr inhibitors |
KR20180064534A (ko) | 2015-11-02 | 2018-06-14 | 바이오아트라, 엘엘씨 | 조건부 활성 폴리펩티드 |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
EP3395835B1 (en) * | 2015-12-25 | 2021-02-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody having enhanced activity, and method for modifying same |
EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | ANTIBODIES AND CONJUGATES THEREOF |
JP7438662B2 (ja) | 2016-01-25 | 2024-02-27 | ジェネンテック, インコーポレイテッド | T細胞依存性二重特異的抗体をアッセイするための方法 |
EP3430054B1 (en) | 2016-03-15 | 2021-12-29 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
US11365256B2 (en) | 2016-06-08 | 2022-06-21 | Xencor, Inc. | Methods and compositions for inhibiting CD32B expressing cells in IGG4-related diseases |
US11858980B2 (en) * | 2016-08-02 | 2024-01-02 | Visterra, Inc. | Engineered polypeptides and uses thereof |
CN116271014A (zh) | 2016-08-05 | 2023-06-23 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
EP3497440A1 (en) | 2016-08-15 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
MX2019007801A (es) | 2016-12-28 | 2019-10-30 | Genentech Inc | Tratamiento de cáncer avanzado con expresión de her2. |
JP6974500B2 (ja) * | 2017-01-13 | 2021-12-01 | ハンクス バイオファーマシューティクス,インコーポレイテッド | FcRnに対するIgG様抗体の結合親和性を増加し、その血清半減期を延長させる方法 |
CN115089704A (zh) | 2017-01-17 | 2022-09-23 | 基因泰克公司 | 皮下her2抗体配制剂 |
KR20230144110A (ko) | 2017-03-02 | 2023-10-13 | 제넨테크, 인크. | Her2-양성 유방암 어쥬번트 치료 |
KR20190140952A (ko) | 2017-04-24 | 2019-12-20 | 제넨테크, 인크. | 막관통 및 인접막 도메인에서의 erbb2/her2 돌연변이 |
CN111405910A (zh) * | 2017-05-10 | 2020-07-10 | 阿尔巴朱纳治疗有限公司 | 具有高HIV抗病毒和免疫调节双重活性的Fc融合蛋白衍生物 |
WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT |
KR20200049764A (ko) | 2017-09-29 | 2020-05-08 | 추가이 세이야쿠 가부시키가이샤 | 혈액 응고 제 viii 인자(fviii) 보인자 기능 대체 활성을 갖는 다중특이성 항원 결합 분자 및 당해 분자를 유효 성분으로서 함유하는 약학적 제제 |
US11802154B2 (en) | 2017-12-20 | 2023-10-31 | Alexion Pharmaceuticals, Inc. | Humanized anti-CD200 antibodies and uses thereof |
KR20200115568A (ko) * | 2018-01-26 | 2020-10-07 | 젠자임 코포레이션 | FcRn에 대한 증진된 결합 및 연장된 반감기를 갖는 Fc 변이체 |
KR20200132938A (ko) | 2018-03-15 | 2020-11-25 | 추가이 세이야쿠 가부시키가이샤 | 지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법 |
CN113227134A (zh) | 2018-12-05 | 2021-08-06 | 株式会社梅花治疗 | 抗体的Fc区变体 |
MA54657A (fr) | 2019-01-03 | 2021-11-10 | Invetx Inc | Compositions pour augmenter la demi-vie d'un agent thérapeutique chez les chiens et procédés d'utilisation |
US20220153875A1 (en) | 2019-03-19 | 2022-05-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
EP3956664A1 (en) | 2019-04-18 | 2022-02-23 | Genentech, Inc. | Antibody potency assay |
AR119264A1 (es) | 2019-06-05 | 2021-12-09 | Genentech Inc | Método para reutilización de cromatografía |
WO2021048330A1 (en) * | 2019-09-13 | 2021-03-18 | CSL Behring Lengnau AG | Recombinant igg fc multimers for the treatment of immune complex-mediated kidney disorders |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
US20230001024A1 (en) * | 2019-11-08 | 2023-01-05 | North Carolina State University | Cross-linking compounds and methods of use thereof |
IL293310A (en) | 2019-12-18 | 2022-07-01 | Hoffmann La Roche | Bispecific anti-ccl2 antibodies |
CA3176434A1 (en) | 2020-04-17 | 2021-10-21 | Zoetis Services Llc | Feline antibody variants |
PE20230108A1 (es) | 2020-04-17 | 2023-01-25 | Zoetis Services Llc | Variantes de anticuerpos caninos |
BR112022022922A2 (pt) | 2020-05-11 | 2023-01-17 | Invetx Inc | Composições para aumentar a meia-vida de um agente terapêutico em caninos e métodos de uso |
BR112022023570A2 (pt) * | 2020-05-20 | 2023-01-24 | Zymeworks Bc Inc | Variantes da região fc de imunoglobulina que compreendem mutações que potencializam estabilidade |
WO2021234655A2 (en) * | 2020-05-21 | 2021-11-25 | Cadila Healthcare Limited | Fc variant and preparation thereof |
WO2021251438A1 (ja) | 2020-06-10 | 2021-12-16 | 株式会社バイカ・セラピュティクス | エリスロポエチンポリペプチドを含む融合タンパク質 |
EP4172193A1 (en) | 2020-06-29 | 2023-05-03 | Zoetis Services LLC | Feline antibody variants for improving stability |
MX2023000500A (es) | 2020-07-10 | 2023-04-12 | Invetx Inc | Composiciones para aumentar la semivida de un agente terapeutico en felinos y modos de uso. |
AR123636A1 (es) | 2020-09-28 | 2022-12-28 | Zoetis Services Llc | Variantes de anticuerpos caninos |
US20230382986A1 (en) | 2020-09-29 | 2023-11-30 | Zoetis Services Llc | Feline antibody variants |
CA3202089A1 (en) | 2020-11-20 | 2022-05-27 | Zoetis Services Llc | Bovine antibody variants |
CA3202074A1 (en) | 2020-12-18 | 2022-06-23 | Zoetis Services Llc | Mutations in feline antibody constant regions |
WO2022165067A2 (en) | 2021-01-28 | 2022-08-04 | Zoetis Services Llc | Mutations in canine antibody constant regions |
AU2022295067A1 (en) | 2021-06-18 | 2023-12-21 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
WO2023108115A1 (en) * | 2021-12-10 | 2023-06-15 | Board Of Regents, The University Of Texas System | Ph-selective antibody fc domains |
US20230364020A1 (en) | 2022-04-01 | 2023-11-16 | Genentech, Inc. | Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides |
WO2023245105A1 (en) | 2022-06-17 | 2023-12-21 | Genentech, Inc. | Use of kosmotropes to enhance yield of an affinity chromatography purification step |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4752601A (en) * | 1983-08-12 | 1988-06-21 | Immunetech Pharmaceuticals | Method of blocking immune complex binding to immunoglobulin FC receptors |
US5985599A (en) * | 1986-05-29 | 1999-11-16 | The Austin Research Institute | FC receptor for immunoglobulin |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
WO1988007089A1 (en) * | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5576184A (en) * | 1988-09-06 | 1996-11-19 | Xoma Corporation | Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
GB8916400D0 (en) * | 1989-07-18 | 1989-09-06 | Dynal As | Modified igg3 |
US5364930A (en) * | 1990-10-16 | 1994-11-15 | Northwestern University | Synthetic C1q peptide fragments |
DE69233254T2 (de) * | 1991-06-14 | 2004-09-16 | Genentech, Inc., South San Francisco | Humanisierter Heregulin Antikörper |
EP0640094A1 (en) * | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US5648821A (en) * | 1993-09-29 | 1997-07-15 | Becker; Ricky C. | Remote cursor control apparatus |
US5783186A (en) * | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6037454A (en) * | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) * | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
WO2000042072A2 (en) * | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7183387B1 (en) * | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2341060B1 (en) * | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
AU2002351353A1 (en) * | 2001-12-19 | 2003-09-02 | Genentech, Inc. | Stabilizing polypeptides which have been exposed to urea |
RU2004127458A (ru) * | 2002-02-14 | 2005-10-27 | Иммуномедикс, Инк. (Us) | Анти-cd20 антитела, их гибридные белки и способы их использования |
US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7365168B2 (en) * | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
AR042485A1 (es) * | 2002-12-16 | 2005-06-22 | Genentech Inc | Anticuerpo humanizado que se une al cd20 humano |
US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP1742660A2 (en) * | 2004-04-16 | 2007-01-17 | Genentech, Inc. | Treatment of disorders |
MXPA06011824A (es) * | 2004-04-16 | 2006-12-15 | Genentech Inc | Ensayo para anticuerpos. |
-
2005
- 2005-08-19 KR KR1020087018673A patent/KR20080080675A/ko not_active Application Discontinuation
- 2005-08-19 ZA ZA200701715A patent/ZA200701715B/en unknown
- 2005-08-19 CN CNA2005800358260A patent/CN101052654A/zh active Pending
- 2005-08-19 BR BRPI0515230-5A patent/BRPI0515230A/pt not_active IP Right Cessation
- 2005-08-19 AU AU2005285347A patent/AU2005285347A1/en not_active Abandoned
- 2005-08-19 JP JP2007528036A patent/JP2008510466A/ja active Pending
- 2005-08-19 WO PCT/US2005/029511 patent/WO2006031370A2/en active Application Filing
- 2005-08-19 CA CA002577133A patent/CA2577133A1/en not_active Abandoned
- 2005-08-19 RU RU2007109785/13A patent/RU2367667C2/ru not_active IP Right Cessation
- 2005-08-19 KR KR1020077006169A patent/KR20070057839A/ko not_active Application Discontinuation
- 2005-08-19 EP EP05808736A patent/EP1778728A2/en not_active Withdrawn
- 2005-08-19 US US11/208,422 patent/US20060067930A1/en not_active Abandoned
-
2007
- 2007-02-01 IL IL181109A patent/IL181109A0/en unknown
- 2007-03-16 NO NO20071419A patent/NO20071419L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2367667C2 (ru) | 2009-09-20 |
IL181109A0 (en) | 2007-07-04 |
KR20080080675A (ko) | 2008-09-04 |
RU2007109785A (ru) | 2008-09-27 |
WO2006031370A3 (en) | 2006-11-16 |
NO20071419L (no) | 2007-05-15 |
US20060067930A1 (en) | 2006-03-30 |
WO2006031370A2 (en) | 2006-03-23 |
EP1778728A2 (en) | 2007-05-02 |
KR20070057839A (ko) | 2007-06-07 |
CA2577133A1 (en) | 2006-03-23 |
JP2008510466A (ja) | 2008-04-10 |
AU2005285347A1 (en) | 2006-03-23 |
ZA200701715B (en) | 2008-07-30 |
CN101052654A (zh) | 2007-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0515230A (pt) | polipeptìdeos, anticorpos e ácidos nucléicos isolados, composições, vetor de expressão, células hospedeiras isoladas, método para a produção de um anticorpo, artigos manufaturados, métodos de tratamento e para o alìvio de disfunções, métodos de produção e de seleção de um polipeptìdeo, anticorpo de ligação cd20 humanizado, anticorpo anti-her2 isolado e usos de um anticorpo | |
CN106632674B (zh) | 一种抗pd-1单克隆抗体、其药物组合物及其用途 | |
HRP20191462T1 (hr) | Antitijela usmjerena protiv her-3 i njihove uporabe | |
BRPI0316779B8 (pt) | Anticorpo anti-cd20 humano ou fragmento de ligação ao antígeno do mesmo, seus usos, composição, artigo manufaturado e formulação líquida | |
IL259927B2 (en) | Humanized antibodies against cd73 | |
BRPI0606547A2 (pt) | anticorpo 2h7 humanizado, ácido nucléico isolado, vetor de expressão, célula hospedeira, método para a produção do anticorpo, composição, artigo manufaturado, metódos de tratamento, formulações lìquidas e usos do anticorpo 2h7 humanizado | |
JP2016138129A5 (pt) | ||
UA102061C2 (ru) | Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний | |
JP7209464B2 (ja) | ヒトインターロイキン-2に対する免疫刺激性モノクローナル抗体 | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
PE20071055A1 (es) | Anticuerpos anti mn | |
WO2007109742A3 (en) | Methods for humanizing antibodies and humanized antibodies made thereby | |
BRPI0514068B8 (pt) | anticorpo anti-cd20, e, composição farmacêutica | |
WO2007048037A3 (en) | METHODS FOR GENERATING MONOVALENT IgG | |
NZ587198A (en) | Monoclonal antibodies against the rgm a protein and uses thereof | |
RU2016106115A (ru) | Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения | |
DE60329489D1 (de) | Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon | |
Lee et al. | Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses | |
PH12013500858A1 (en) | Binding proteins, including antibodies, antibody derivatives and antibody fragments that specifically bind cd 154 and uses thereof | |
UA86605C2 (ru) | Антитело, которое содержит вариант исходного человеческого fс-участка | |
AR068566A1 (es) | Proteinas fijadoras de antigeno de factor de crecimiento del tipo factor de crecimiento epidermico fijador de heparina | |
AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
WO2016077734A3 (en) | Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors | |
WO2006033702A3 (en) | Anti-cd154 antibodies | |
WO2008063771A3 (en) | Anti-cd20 antibodies and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012. |